On April 6th, Abionic and Palex joined forces to participate in the first day of GaliSepsis, the National Sepsis Course hosted and organized virtually by the Ourense University Hospital Complex (CHUO) in Spain.
With the aim of updating the most important concepts and reviewing the latest developments in the management of patients with sepsis, three speakers shared their expertise and clinical experiences on the Pancreatic Stone Protein (PSP) biomarker.
Moderated by Profesor Antonio Artigas, Dr Luis García de Guadiana kicked off the session reminding us that over 250 potential sepsis biomarkers have been identified as of 2020, but many of these struggle to meet the necessary criteria for successful implementation into clinical practice. Dr García however, focused on Pancreatic Stone Protein (PSP), which is already available as a POC test (manufactured by Abionic and distributed by Palex in Spain and Portugal) and discussed the research articles that support PSP as a promising biomarker in the early diagnosis of sepsis.
Subsequently, Dr Adrian Ceccato from the Hospital Universitario Sagrado Corazón in Barcelona shared his experience in an ongoing clinical study evaluating the use of PSP as an early biomarker for the identification of ventilator associated pneumonia (VAP), a notorious diagnostic challenge. Preliminary results from Dr Ceccato and colleagues’ cohort showed a significant increase in PSP previous to VAP onset, and ongoing results will hopefully soon confirm this observation.
Today’s burden of COVID-19 cases requiring intensive care hospitalization has given urgent impetus to the research of biomarkers for the prediction of disease course, treatment efficacy and perhaps even more importantly, the early identification of imminent bacterial superinfection.
Dr Maria Cruz Martín Delgado shared results from real-life experiences at the Hospital Universitario de Torrejón. As it happens, they were the first ICU to receive a critically ill COVID-19 patient in Spain last year and have gone through major reorganisations to meet the increasing demand - as have most other ICUs around the world.
Dr Martín shared several clinical case studies of COVID-19 patients where PSP was the only biomarker to remain at basal concentrations despite the severe viral infection impacting organ function, and where PSP later increased by more than 2-fold 48 hours before the clinical diagnosis of a bacterial infection.
These recent real-life experiences and novel clinical data in critically ill adults support the previous findings on the undeniable diagnostic value of PSP for the early identification of severe infection/sepsis. Furthermore, they also demonstrate the easy and practical implementation of PSP measurements on a point of care device, in the heart of an ICU.
My hope for the future is that the increasing availability of rapid biomarker tests at the patient’s bedside will improve the personalization and management of patient care in the ICU.
Romy Benninga, MSc, Medical Affairs Department, Abionic SA
Watch the entire symposium: